Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 8/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | HINT1 | P49773 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235770 | 1.00 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL8669732 | 0.93 | NT5E (0.59) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL1269745 | 0.92 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL6027526 | 0.89 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| SCHEMBL1697432 | 0.89 | NT5E (0.61) | NT5ETGM2IMPDH2FUT5KRAS | |
| L-Fucose SCHEMBL18992533 | 0.89 | TGM2 (0.67) | NT5ETGM2IMPDH2FUT5KRAS | |
| L-Fucose SCHEMBL20607674 | 0.89 | TGM2 (0.67) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL6046180 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL27957333 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS | |
| Glucuronic Acid SCHEMBL5941537 | 0.87 | TGM2 (0.66) | NT5ETGM2IMPDH2FUT5KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025015168-A1 | CELL-FREE PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES (HMOS) | Debut Biotechnology, Inc. (US) | 2025-01-16 | — | — | WO | claimed |
| EP-1426441-B1 | ALPHA-1,2-FUCOSYL TRANSFERASE AND DNA ENCODING THE SAME | KYOWA HAKKO BIO CO LTD (JP) | 2010-05-19 | — | — | EP | claimed |
| US-6875591-B1 | Process for producing GDP-fucose | KYOWA, HAKKO KOGYO CO., LTD. (JP) | 2005-04-05 | — | — | US | claimed |
| US-20040219553-A1 | Alpha-1,2-fucosyltransferase and dna encoding the same | KYOWA HAKKO KOGYO CO. LTD. (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1426441-A1 | ALPHA-1,2-FUCOSYL TRANSFERASE AND DNA ENCODING THE SAME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-09 | — | — | EP | claimed |
| US-20020068331-A1 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | WONG CHI-HUEY (US) | 2002-06-06 | — | — | US | claimed |
| US-6319695-B1 | FORMING A GLYCOSIDE BOND BY ETHERIFICATION AND CIRCULATION | THE SCRIPPS RESEARCH INSITUTE | 2001-11-20 | — | — | US | claimed |
| EP-1076096-A1 | Process for producing GDP-fucose | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-14 | — | — | EP | claimed |
| EP-0642526-A4 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. | SCRIPPS RESEARCH INST (US) | 1996-04-10 | — | — | EP | claimed |
| EP-0642526-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | claimed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025015168-A1 | CELL-FREE PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES (HMOS) | Debut Biotechnology, Inc. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| EP-0642526-B1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | SCRIPPS RESEARCH INST (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0870841-A1 | PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0642526-A4 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. | SCRIPPS RESEARCH INST (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0642526-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | NT5E 416/4885TGM2 116/4885IMPDH2 390/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | NT5E 857/4885TGM2 533/4885IMPDH2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.